EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 449 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR This 11-Year-Old Is Starting College Next Year With A Plan To... December 31, 2021 FDA Recognises OncoKB Database of Molecular Tumour Marker Information October 8, 2021 Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Load more HOT NEWS Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma... Today is Veterans Day FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC
